An observational study in Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis and Liver Fibrosis, sponsored by Chongqing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-02-12.
Sponsored by Chongqing Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Fatty Liver with a site in China — 31 open to participants now, 35 under way, 2 of them phase 3. Fatty Liver · China.
Among the 64 studies in Fatty Liver with a site in China, this one is the 3rd largest by planned enrollment of the 27 observational ones that give a count, is one of 3 that started in 2023, is one of 27 observational ones, reaches primary completion later than 13 of the 34 other live ones, and was the 27th registered.
666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.
Browse Fatty Liver studies →31 of the 64 studies in Fatty Liver with a site in China are open now. Recruiting first, the newest first:
Li Lab,MD · Sites in China
Ages 18–74
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
West China Hospital · Sites in China
Ages 18–60
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Hudson Biotech · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 4 · Phase 4 4
First in 2004; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 7,000 is above the median of 150 across 207 observational studies indexed under Fatty Liver.
Median enrollment 90 across the 37 interventional studies, 400 across the 27 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 64 have an industry lead sponsor. The 10 most frequent:
Chongqing Medical University is the lead sponsor of 78 studies on the registry; 17 are open to participants now.
Chongqing Medical University has 1 study filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
9 of the studies in Fatty Liver with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06268262The Affiliated Hospital of Xuzhou Medical UniversitySurgical-imaging Research on Obesity (SIRO) | 2026-12 |
| NCT05974904Chongqing Medical UniversityAssociation of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study | 2026-12-28 |
| NCT07481734Hudson BiotechTesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease | 2027-02-14 |
| NCT07462455Xiamen Amoytop Biotech Co., Ltd.Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) | 2027-02-28 |
| NCT07807059Fujian Shengdi Pharmaceutical Co., Ltd.A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment | 2027-03-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 64 studies in Fatty Liver with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD).
The main question[s] it aims to answer are:
[question 1] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? [question 2] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?
Background Inflammation is related to the occurrence and development of fatty liver. Our research aimed to investigate the link between an inflammatory indicator, high-sensitivity C-reactive protein to albumin ratio (hsCAR), and metabolic dysfunction-associated fatty liver disease (MAFLD).
Methods Ultrasonic indices were used to evaluate the severity of liver steatosis and fibrosis of participants from the NHANES database, respectively. The relationship between hsCAR and MAFLD was explored using multivariate logistic regression analysis, restricted cubic splines (RCS) as well as threshold analysis. Finally, subgroup analyses were performed using the same methodology.
They all come from the National Health and Nutrition Examination Survey, which is a database that contains information about demographics, dietary, examination, laboratory and questionnaire of the American population obtained through sophisticated sampling strategies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants diagnosed with MAFLD. Metabolic dysfunction-associated fatty liver disease (MAFLD) is the term used to describe hepatic steatosis in the presence of metabolic abnormalities, excess weight, obesity, or type 2 diabetic mellitus.
If presence of at least two metabolic risk abnormalities:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
controlled attenuation parameter\<274 dB/m
controlled attenuation parameter ≥ 274 dB/m
Other: high-sensitivity C-reactive protein to albumin ratio
liver stiffness measurement \< 8.2 kPa
liver stiffness measurement ≥ 8.2 kPa
Other: high-sensitivity C-reactive protein to albumin ratio
High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.
Controlled attenuation parameter
Controlled attenuation parameter is an ultrasound indicator measured by FibroScan to evaluate the degree of liver steatosis
Time frame: at baseline
Liver stiffness measurement
Liver stiffness measurement is an ultrasound indicator measured by FibroScan to evaluate the degree of liver stiffness
Time frame: at baseline
Plan to share: No
Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chongqing Medical University